Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
KYORIN Pharmaceutical Co Ltd (Kyorin), formerly KYORIN Holdings Inc, develops, manufactures, and markets pharmaceutical products, including innovative prescription medicines, generic drugs, and over-the-counter (OTC) offerings. The company also provides diagnostics, reagents, intermediates, industrial chemicals, and other related products. Kyorin sells its portfolio under brands such as Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, and Rubysta, among others. In addition, it delivers support and solutions to healthcare professionals, with a particular focus on infection-related fields. The company conducts its operations in Japan through subsidiaries including Kyorin Rimedio Co Ltd and Kyorin Pharmaceutical Group Facilities Co Ltd, supporting manufacturing and facility functions. Kyorin is headquartered in Chiyoda-Ku, Japan.
Headquarters
Japan
Address
1-3-7 Otemachi, Nihon Keizai Shimbun Tokyo Head Office Building, Chiyoda-Ku, 100-0004
Website
www.kyorin-pharm.co.jp
Telephone
81 3 63749700
No of Employees
1,982
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4569 (TYO)
Revenue (2025)
$811.3M
-2.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-62%
(2025 vs 2024)
Market Cap*
$440.2M
Net Profit Margin (2025)
XYZ
-60.9%
(2025 vs 2024)
* As of and is in US$
KYORIN Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| OTC Drugs: | Subcontracted Drug Manufacturing | Cool One |
| Cool One Damming GX- Cough | Lasvic | |
| Cool One Nasal Spray- Stuffy Nose, Head Congestion, Sneeze and Running Nose | Lifnua | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In October, the company entered into a collaboration and license agreement with Hinge Bio Inc for HB2198, a new drug candidate for systemic lupus erythematosus (SLE). |
| 2025 | Contracts/Agreements | In March, the company entered into a license agreement with Novartis Pharma AG, for KRP-M223, a compound discovered in-house, and its backup compounds. |
| 2024 | Contracts/Agreements | In August, the company entered into an agreement with EverMed Inc for airway epithelial cell-derived extracellular vesicles drug discovery. |
Competitor Comparison
| Key Parameters | KYORIN Pharmaceutical Co Ltd | Astellas Pharma Inc | Teijin Ltd | Santen Pharmaceutical Co Ltd | Nippon Shinyaku Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chiyoda-Ku | Chuo-Ku | Chiyoda-Ku | Osaka | Kyoto |
| State/Province | Tokyo | Tokyo | Tokyo | Osaka | Kyoto |
| No. of Employees | 1,982 | 13,643 | 15,689 | 3,849 | 2,309 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yutaka Ogihara | President; Director; Chief Executive Officer | Executive Board | 2023 | - |
| Yasuji Kurose | Chief Strategy Officer; Chief Financial Officer; Director; Director - Corporate Planning | Executive Board | 2024 | - |
| Kenichi Nakamura | President - KYORIN Pharmaceutical Group Facilities Co., Ltd; Corporate Officer; Chief Medical Officer | Senior Management | 2026 | - |
| Noriaki Tamura | Chief Communications Officer; Corporate Officer; Senior Director- Sales and Marketing | Senior Management | - | - |
| Junichi Ishiyama | General Manager - Intellectual Property Department; Chief Scientific Officer; Corporate Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer